CQ HealthBeat: Ebola Drug Attracts $38 Million in BARDA Funds, Moves Toward Human Tests
“As much as $38 million in federal funds may be provided under a new agreement for the development of Regeneron Pharmaceuticals Inc.’s Ebola treatment, with an aim of advancing it toward tests in people. … [The Biomedical Advanced Research and Development Authority (BARDA)] on Sept. 14 announced a $28.5 million agreement with Johnson & Johnson for work on an Ebola vaccine…” (Young, 9/21).